Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently received significant media coverage for their compelling efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1 receptor agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1 receptor agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases, which has opened the door to potential new indications and label expansions for this drug class. 

This panel discussion hosted by the Pharmaceutical & BioScience Society will explore the evolution of these and other agents (e.g. gastric inhibitory polypeptide [GIP] receptor agonists), including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes. Expect to hear more about:

• Diabetes / obesity and treatments
• GLP-1 receptor agonists for diabetes and obesity: evolution and current marketed therapies, clinical efficacy and safety
• GIP receptor agonists and dual GLP-1/GIP receptor agonists
• Market landscape: revenues, HCP perspectives, consumer viewpoints, access and reimbursement
• GLP-1 in other indications: CV, kidney disease, MASH
• On the horizon: the obesity clinical pipeline, IP landscape, and the potential arrival of generics

Ipsos’ Scott Morano and Roberto Cortese will be among the expert panelists. For more information, simply click here to register.